Used in the treatment of iron overload disorders such as hemochromatosis and chronic anemia conditions including beta-thalassemia. This antibody targets ferroportin, the primary iron export protein, modulating iron release from cells like enterocytes and macrophages. By stabilizing ferroportin, it helps regulate systemic iron levels, reducing iron accumulation in tissues. It is also investigated for managing inflammation-driven anemia and conditions where hepcidin dysregulation occurs. Its therapeutic action supports improved iron homeostasis without the need for frequent phlebotomy or chelation therapy.